DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages



Author: George Shand, Final Year Medical Student, University of Auckland, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, August 2015.


What is afamelanotide?

Afamelanotide (SCENESSE®, Clinuvel Pharmaceuticals) is a potent alpha-melanocyte-stimulating hormone (αMSH) analogue, which stimulates the production of eumelanin in the skin — a tan, induces antioxidant activities, enhances DNA repair processes, and modulates inflammation. This injectable synthetic melanotropic peptide was previously known as Melanotan I.

Eumelanin is a form of melanin, the tanning pigment in the skin. Production of melanin is usually stimulated by exposure to the ultraviolet (UV) radiation component of sunlight.

  • Exposure to UV radiation causes cellular damage that increases the risk of skin cancer.
  • A tan protects the skin from further damage by absorbing UV radiation.
  • Melanin also filters out longer wavelengths, providing protection to people with visible light photosensitivity.
  • Melanin also has antioxidant effects to protect skin against free radicals. Free radicals are responsible for the symptoms experienced in erythropoeitic protoporphyria.

What skin conditions respond to afamelanotide?

Afamelanotide is registered, in some countries, to treat erythropoietic protoporphyria. It has been reported to be of benefit to patients with:

Erythropoietic protoporphyria

Erythropoietic protoporphyria (EPP) is a rare, inherited disorder of metabolism typically manifesting in early childhood as painful photosensitivity. One to 20 minutes after sun exposure, patients experience burning pain on exposed skin, usually hands and face, followed by swelling and redness that lasts for several days. The fear of this pain can have a major effect on quality of life including work and recreational opportunities.

Afamelanotide has been shown through Phase III studies to decrease phototoxic reactions and recovery time in patients with erythropoietic protoporphyria. Afamelanotide was approved for treatment of erythropoietic protoporphyria by the European Medicines Agency (EMA) in 2016 and by the FDA in the US in October 2019. It reduces pain and allows nearly all patients to be outdoors for longer periods than previously. However it has no effect on the number or duration of phototoxic reactions. Quality of life is significantly improved. Sunlight avoidance and wearing protective clothing remains essential; afamelanotide is not a cure for EPP.

Solar urticaria

Solar urticaria is a rare form of chronic physical or inducible urticaria characterized by itch, weal and flare within minutes of sunlight exposure. The action spectrum (the part of  the electromagnetic spectrum that causes symptoms) is variable, but most often involves long wavelength UVA and visible light. The use of afamelanotide has been shown under experimental conditions to reduce weal formation secondary to increased melanisation.


Vitiligo is a disorder characterised by white patches of skin due to selective loss of epidermal melanocytes. UVB phototherapy is a cornerstone of vitiligo management; however repigmentation has been shown to be faster and superior when phototherapy is used in conjunction with afamelanotide.

Hailey-Hailey disease

Afamelanotide was prescribed to 2 patients with Hailey-Hailey disease (benign familial pemphigus) resulting in remission

Does afamelanotide work as a sunscreen?

The use of afamelanotide has been associated with a 50% decrease in epidermal sunburn cells, as well as a significant reduction in thymine dimer formation (part of the process by which UVB damages DNA). However, the marketers of afamelanotide do not recommend its use as a sunscreen or treatment of sunburn.

Contraindications to afamelanotide

Because no data is available, contraindications to afamelanotides include:

  • Liver or kidney impairment: the metabolism of this drug is not completely understood.
  • Children: the safety and efficacy of this drug in people aged 0 to 17 years has not yet been established.
  • The elderly: it is also recommended that patients over 70 do not take afamelanotide.
  • Pregnancy: it is recommended that women who are pregnant or breastfeeding should not take it.

How to take afamelanotide

Afamelanotide (Scenesse®) comes as a white rod approximately 1.7 cm in length and 1.5 mm in diameter. It contains 16 mg of afamelanotide and is implanted under the skin, usually around the hip. It should be inserted by a specialist physician every 2 months, prior to and during increased sunlight exposure (eg, summer). It is recommend to have three implants per year, with a maximum of four per year.

The patient is asked to wait for 30 minutes in case of allergic reaction to it.

Tests before/after starting afamelanotide

Tests before starting afamelanotide may include:

  • Liver and kidney function
  • Pregnancy test

Additional tests may be necessary for those with heart or breathing problems, diabetes, Cushing disease, Addison disease, Peutz-Jeghers syndrome, epilepsy, anaemia or skin cancer.

Regular full-body skin examinations are recommended prior to and every six months during treatment to assess and monitor pigmented lesions and other skin abnormalities, especially in those with a personal history of skin cancer.

Side effects of afamelanotide

Few major side effects have been reported thus far.

  • One-third of patients experience hyperpigmentation at the implant site
  • There is a low risk of darkening moles anywhere on the body
  • Mild tiredness, headache, dizziness and nausea are common after administration of the implant usually clears by 72 hours.

There is no evidence that afamelanotide increases the risk of melanoma. The primary risk factor for melanoma is UVB irradiation. Eumelanin production reduces UVB skin penetration and scavenges free radicals, hence protecting the skin.

Drug interactions with afamelanotide

Due to the method of administration, patients taking blood thinning medication may experience bruising or bleeding at the site of implantation.

No specific drug interactions have been identified to date (2015).

Safety measures

  • Women of childbearing potential should use effective contraception during treatment with afamelanotide, and for a period of three months after.
  • Patients are recommended not to drive or use heavy machinery within 72 hours of administration of afamelanotide due to the risk of tiredness and dizziness.
New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.



  • Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FP, Sijbrands EJ, de Rooij FW, Lebwohl M, Naik H, Goding CR, Wilson JH, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015 Jul 2;373(1):48–59. doi: 10.1056/NEJMoa1411481. PubMed
  • Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015 Jan;151(1):42–50. doi: 10.1001/jamadermatol.2014.1875. PubMed
  • Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol. 2011 Feb;164(2):407–14. doi: 10.1111/j.1365-2133.2010.10104.x. PubMed
  • Biba E. Protection: the sunscreen pill. Nature. 2014 Nov 20;515(7527):S124-5. doi: 10.1038/515S124a. PubMed
  • Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, Humphrey SM, Kleinig MJ. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006 Aug;126(8):1869–78. Epub 2006 Jun 8. PubMed
  • SCENESSE. Summary of product characteristics. European Comission 2015; February 12. 27 p. PDF file
  • Biolcati G, Aurizi C, Barbieri L, Cialfi S, Screpanti I, Talora C. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol. 2014 Mar;39(2):168–75. doi: 10.1111/ced.12203. Epub 2013 Oct 25. PubMed PMID: 24256215; PubMed Central
  • McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH. Afamelanotide in the treatment of dermatologic disease. Skin Therapy Lett. 2018;23(6):6–10. Journal
  • Wensink D, Wagenmakers MAEM, Barman-Aksözen J, et al. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol. 2020;156(5):570–5. doi:10.1001/jamadermatol.2020.0352 PubMed Central
  • Wu J, Cotliar R. Afamelanotide: an orphan drug with potential for broad dermatologic applications. J Drugs Dermatol. 2021;20(3):290–4. doi:10.36849/JDD.5526 PubMed

On DermNet

Other websites

Books about skin diseases


Related information

Sign up to the newsletter